Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

被引：6
|
作者：
Remon, Jordi [1 ]
Hendriks, Lizza [2 ]
Aspeslagh, Sandrine [3 ]
Besse, Benjamin [4 ,5 ]
机构：
[1] HM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
[2] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Pulm Dis Dept, Maastricht, Netherlands
[3] UZ Brussels VUB, Dept Med Oncol, Brussels, Belgium
[4] Gustave Roussy, Dept Canc Med, Villejuif, France
[5] Univ Paris Saclay, Orsay, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
LUNG-CANCER; EFFICACY; SAFETY;
D O I：
10.1016/j.jtho.2019.07.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1701 / 1703
页数：3
相关论文
共 50 条
  • [41] Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors
    Han, G.
    Bi, J.
    Li, Y.
    Pi, G.
    Pi, H.
    Li, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S581 - S581
  • [42] Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC
    Shohdy, Kyrillus S.
    Abdel-Rahman, Omar
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (17)
  • [43] Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
    Walia, Anushka
    Prasad, Vinay
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (11) : 9513 - 9515
  • [44] Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
    Anushka Walia
    Vinay Prasad
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 9513 - 9515
  • [45] Future directions in immune-checkpoint inhibitors in NSCLC
    Hayashi, Hidetoshi
    CANCER SCIENCE, 2018, 109 : 1225 - 1225
  • [46] Hyperprogressive NSCLC With Two Immune- Checkpoint Inhibitors
    Kasparian, Saro
    Gentille, Cesar
    Burns, Ethan
    Bernicker, Eric H.
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (02):
  • [47] Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
    Gomatou, Georgia
    Charpidou, Andriani
    Li, Peifeng
    Syrigos, Nikolaos
    Gkiozos, Ioannis
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 1426 - 1437
  • [48] The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Zhou, J.
    Donaubauer, A.
    Frey, B.
    Becker, I.
    Rutzner, S.
    Sun, R.
    Ma, H.
    Fietkau, R.
    Deutsch, E.
    Gaipl, U.
    Hecht, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S336 - S336
  • [49] Exploration of Factors Relating to Paradoxical Immune Response in Patients Treated with Immune Checkpoint Inhibitors for NSCLC
    Cardona, A. F.
    Arrieta, O. G.
    Ruiz-Patino, A.
    Zatarain Barron, Z. L.
    Rojas, L. L.
    Corrales, L.
    Martin, C.
    Barron, F.
    Sotelo, C.
    Rodriguez, J.
    Ricaurte, L.
    Freitas, H.
    Cordeiro De Lima, V.
    Mas, L.
    Avila, J.
    Bravo, M.
    Mayorga, D.
    Archila, P.
    Otero, J.
    Carranza, H.
    Vargas, C.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S971 - S971
  • [50] Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma
    Bishop, Andrew J.
    Amini, Behrang
    Lin, Heather
    Raza, Shaan M.
    Patel, Shreyaskumar
    Grosshans, David R.
    Ghia, Amol
    Farooqi, Ahsan
    Guadagnolo, B. Ashleigh
    Mitra, Devarati
    Akdemir, Kadir C.
    Lazar, Alexander J.
    Wang, Wei-Lien
    Alvarez-Breckenridge, Christopher
    Bird, Justin
    Rhines, Laurence D.
    Somaiah, Neeta
    Conley, Anthony P.
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (08) : 374 - 378
12345